Pulmonary toxicity resulting from treatment with gemcitabine

Onkologie

Volumn 22, Issue 2, 1999, Pages 146-149

  Fuxius, S ^b   Unger, C ^b   Mross, Klauss ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

Acute RDS; Gemcitabine; Toxicity

Indexed keywords

DEXAMETHASONE; GEMCITABINE; PREDNISOLONE;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CASE REPORT; ESOPHAGUS CANCER; FEMALE; HUMAN; LUNG TOXICITY; LYMPH NODE METASTASIS; MALE; OVARY CANCER; PANCREAS ADENOCARCINOMA; SKIN METASTASIS; TREATMENT PLANNING;

EID: 0032907152     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026934     Document Type: Article

References (17)

1. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris A: Advanced breast cancer: A phase II trial with Gemcitabine. J Clin Oncol 1995;13:2731-2736.
2. Carmichael J, Fink U, Russel RCG, Spittle MF, Harris AL, Spiessi G, Blatter J: Phase II study with Gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-105.
3. Rothenhcrg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo A-M, Von Hoff DD: A phase II study of Gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-353.
4. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of Gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 1994;12:1535-1540.
5. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly Gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1994;12:1821-1826.
6. Plukett W, Huang P, Xu Y-Z, Heinemann V, Grunewald R, Gandhi V: Gemcitabine metabolism, mechanisms of action and self-potentiation. Semin Oncol 1995;22:suppl 11, pp 3-10.
7. Allegra CJ, Grem JL: Antimetabolites; in DeVita VT, Hellman S, Rosenberg SA: Cancer, Principles and Practice of Oncology. Lippincott-Raven, Philadelphia 1997.
8. Semsek D, Unger C: Gemcitabin - Ein neues Zytostatikum. Krankenhauspharmazie 1996;17:260-265.
9. Aapro MS, Martin C, Hatty S: Gemcitabine - a safety review. Anti-Cancer Drugs 1998;9:192-201.
10. Kneifel B, Brusa-Düwel P, Becker K, Platz D, Arning M, Kleeberg UR: Oral dexamethasone for the amelioration of the gemcitabine-induced side effects asthenia, edema, and flu-like symptoms. Onkologie 1998;21:229-231.
11. Riede U-S, Costabel U: Tracheobronchialsystem; in Riede U-N, Wehner H: Allgemeine und spezielle Pathologie. Thieme, Stuttgart 1986.
12. Kollef MH, Schuster DP: The acute respiratory distress syndrome. N Engl J Med 1995;332:27-37.
13. Kirste T, Hauns B, Eichelmann A, Brinkmann R, Beller J, Mross K, Unger C: Complete remission in patients with pancreatic cancer: A rare but sometimes achievable event. Onkologie 1998;21:64-66.
14. Kassem B, Miketic LM, Landreneau RJ, Ferson PF, Keenan R, Yousem SA, Gooding WE, Lindberg CA, Trenn MR, Ponas RS: Phase I study of Gemcitabine, given weekly as short infusion. Proc Annu Meet Am Soc Clin Oncol 1990;14:A1190.
15. Pavlakis N, Bell DR, Millward MJ, Levi JA: Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997;80:286-291.
16. Tempero MA, Brand R: Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1998;82:1800.
17. Marruchella, Fiorenzano G, Merizzi A, Rossi G, Chiodera PL: Diffuse alveolar damage in a patient treated with Gemcitabine. Eur Resp J 1998;11: 504-506.